TAKE Solutions Ltd. Enabling Business Efficiencies Corporate - - PowerPoint PPT Presentation
TAKE Solutions Ltd. Enabling Business Efficiencies Corporate Presentation TAKE : T echnology, A nalytics & K nowledge for the E nterprise Contents TAKE At A Glance Business Model & Market Potential Competencies Life
Corporate Presentation
Enabling Business Efficiencies
TAKE: Technology, Analytics & Knowledge for the Enterprise
2
TAKE – At A Glance Business Model & Market Potential Competencies
− Life Sciences − Supply Chain Management
Financials Growth Strategies & Key TAKEaways Appendix
3
Headquartered in Chennai, India, TAKE Solutions Ltd.
delivers technology, services and expert advice in Life Sciences and Supply Chain Management domains
Strong presence in US, Europe and Middle East Asia: US
contributes approx. 2/3 of revenue
CMMi Level 5 accredited company Corporate
Sponsor
Clinical Data Interchange Standards Consortium (CDISC) and ACI has a Registered Solution Provider (RSP) status
Recognitions:
markets
industry expertise and overall customer satisfaction in Life Sciences domain
Technology Magazine
We serve 410+ clients through 14 offices globally
with 1,250+ employees
Life Sciences: Celgene, Eisai, Johnson & Johnson,
Merck, Neuromed, Novartis, Pfizer, Roche, Sanofi Aventis
SCM: Applied Materials, Alcoa, GE Group,
Honeywell, Panasonic, ITC, Pepsi, Transocean, Xerox
About TAKE Marquee Clients Financials
FY12 Revenue : INR 7,037 million FY12 Net Profit: INR 856 million
2,500 5,000 7,500 FY08 FY09 FY10 FY11 FY12 INR million Revenue Net Profit
4
Chennai, India Austin, TX Philadelphia, PA Muscat, Oman Princeton, NJ
TAKE Solutions Inc. 502 Carnegie Center, Suite 100, Princeton, NJ
USA HQ
TAKE Solutions Ltd. No.8B, Adyar Club Gate Road, Chennai - 600028, India
Global HQ
Riyadh, Jeddah & Al-Khobar Saudi Arabia Dubai, UAE
Strong Presence in the US, Middle East Asia and Europe
Hampshire, UK
TAKE Solutions LLP Shriram "The Gateway SEZ", Perungalathur, Chennai, India
Global Delivery Center
Singapore Abraq Khaitan, Kuwait
5
CMMi Level 5
2011: IDC, a global market intelligence firm, ranked TAKE as Leader in the life science R&D IT outsourcing market based
with what customers will require in three to five years
2011 Supply & Demand Chain Executive 100 list
2010: A premier global analyst firm recognized and ranked TAKE, first among large system integrators for industry expertise & overall customer satisfaction in the Life Sciences Domain
2010 Great Supply Chain Partner by SupplyChainBrain
2010 “Editors’ Pick” Distinction by Consumer Goods Technology Magazine
Global Logistics & Supply Chain Strategies 2010: 100 Great Supply Chain Partners List
2010: Listed in Food Logistics 100 for Fourth Consecutive Year
Manufacturing Business Technology Emerging 40 Vendor List (USA)
Madras Management Association (MMA) Award 2010 for Managerial Excellence in the Services Category Oracle Gold Partner SAP Business Objects Gold Partner Microsoft BIO IT alliance Partner CDISC Solutions Partner Microsoft’s Digital Pharma Initiative Microsoft High Impact Gold partner Others: Cegedim Relationship Management,
QlikTech, & Intermec
Certifications & Accreditation Alliances and Partnerships
7
DOMAIN
Supply Chain Management & Life Sciences
TECHNOLOGY
Service Oriented Architecture (SOA) Cloud Computing Virtualization
DELIVERY model REVENUE model
SaaS On Premise Business Services
Embedded / RFID / Mobile Licenses Maintenance
TRANSACTIONS / SUBSCRIPTIONS
Services
8
Balanced: Well distributed across two key verticals - niche offerings addressing multiple
end user industries
Wide Portfolio of Offerings: Solutions to address customer needs - Solutions delivered
as business services, products and SaaS
Diversified Customer Base: Portfolio of solutions to address customer size - focused
approach to large & mid-market customer segment and wider approach to SME segment
Scalable: Platform agnostic solutions to enhance addressable markets and strategic
partnerships to drive penetration in areas of specialization
Diversified Revenue Streams: Income from subscription, licensing, royalties, services and
AMC leading to a mix of annuity and non annuity revenues
9
1.0 8.0 40.0 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 SaaS On Premise Business Services USD billion 5.7 10.2 0.0 2.0 4.0 6.0 8.0 10.0 12.0 Pre - Approval Post- Approval USD billion
Supply Chain Management Life Sciences
11
Discovery Development Commercialization Research Preclinical Phase I Phase II Phase III Phase IV Technology Solutions √ √ √ √ CTMS EDC CDMS eDMS eSub CDR/LSH PV Development Process Services Individual offerings SAS Programming Biostatistics Clinical Data Standardization Document & Submission Publishing Milestone based & Multi-milestone Solutions IND/CTA to NDA Legacy Data Standardization Document & Submission publishing Data Integration & Clinical Data Repository
Kindly refer the Appendix at the end of the presentation for the meanings of the acronyms used above
12
CDISC Accelerators PharmaReady DMS PharmaReady eCTD PharmaReady SPL/PLR PharmaReady TRMS SafetyView PharmaReady PPM
SAS - Bio Statistics Framework
Clinical Development Bio Statistical Programming Regulatory Submissions Safety
pvNet pvConnect PharmaReady eTMF
Oracle Clinical Phase Forward Siebel CTMS IMPACT Argus Safety AERS LSH
13
Clinical Data Warehouses ePublishing NDA/IND/ANDA Document Publishing Document Archival Safety Analytics Safety Signal Detection Core Data Sheets Literature Scanning Case Processing DMCs Data Standardization NDA preparation Biostatistics Programming Data Management
Medical Writing & Coding Trial Master File
14
Customer A Therapeutic Area 1 Indication A Indication B Phase1 Study I Phase2 Study 1 Therapeutic Area 2 Indication C Customer B Therapeutic Area 1 Indication D Indication E Phase1 Study 1 Study 1 Study 1 Phase2 Study 1 Study 1 Study 1 Therapeutic Area 2 Customer C Therapeutic Area 1 Customer D Therapeutic Area 1
TLFs, Biostatistics, SDTM, ADaM, ISS/ISE, DMCs, SAP, EAC, NDAs Increasing customer base Multiplying revenues
15
Unique combination of deep domain expertise and technical skills Market penetration across
Mature infrastructure across USA and APAC
Strategic partnerships with Oracle and Liquent TAKE’s differentiated approach to markets
: Full Service Provider
* SAS 70 (the Statement on Auditing Standards No. 70) defines the standards an auditor must employ in order to assess the contracted internal controls of a service organization. Service organizations, such as hosted data centers, insurance claims processors and credit processing companies, provide outsourcing services that affect the operation of the contracting enterprise.
16
regulatory and safety leading to larger ticket size of contracts
proportion of overall R&D spend
regulatory filing in electronic mode
Management to increase product user base as well as expand addressable customer base
17
“TAKE has built a strong list of clients, based on its deep domain knowledge, willingness to engage customers as partners, IP-based solutions, and thought leadership in clinical, regulatory, drug safety, and other life science areas.” “TAKE's diverse customer base, broad services portfolio, strong commitment to life science industry-specific growth, domain-centric expertise, and strong customer relationships make TAKE is a fierce competitor in winning projects that the company competes for.”
Source: IDC MarketScape: Worldwide Life Science R&D IT Outsourcing 2011 Vendor Assessment, August 2011
Excerpt from the Report:
three to five years
18
Pharmaceutic al Biotechnology Consumer Health Animal Health Crop Science/Agroc hemicals Medical Devices Dietary Supplements Cosmetics Tobacco Generics Turnover > $100m 744 172 63 53 116 128 72 60 46 44 Turnover > $250m 476 123 53 44 100 99 56 52 40 40 Turnover > $500m 351 98 41 38 84 81 43 45 35 32 Turnover > $1b 257 88 34 27 71 60 36 35 29 22 257 88 34 27 71 60 36 35 29 22 351 98 41 38 84 81 43 45 35 32 476 123 53 44 100 99 56 52 40 40 744 172 63 53 116 128 72 60 46 44 200 400 600 800 1000 1200 1400 1600 1800 2000 Number of companies Customer/prospect type
Number of customers/prospects by type
19
North America Europe Africa Asia Australasia South America Generics 49 17 2 13 1 Tobacco 48 13 9 2 Cosmetics 175 1270 3 661 5 Dietary Supplements 150 23 2 34 1 1 Medical Devices 285 79 16 1 Crop Science/Agrochemicals 166 47 2 104 6 30 Animal Health 120 335 95 3 Consumer Health 83 27 2 20 1 Biotechnology 587 162 34 8 Pharmaceutical 4018 3757 33 3139 107 185 1000 2000 3000 4000 5000 6000 7000 Number of customers/prospects Geography
Customers/prospects by geography
20
Bio-Tech CROs / Academic Pharma Generics / OTC Devices
We serve 7 of top 10 global pharmaceutical companies
22
SNG, XPC, Resonance ERM TAKE IPOINT, Take Forward, Take Hub Insight, Cameo, Optima
Value Chain Collaboration
Gemini (Process Manufacturing) Gemini (Discrete Manufacturing) Compliance Label Manager RoutePro
Enterprise Mobility & Auto-ID
SaaS Platform
New generation fulfillment on multi-tenancy model
Products in Pipeline
Gemini for SAP
Products in Pipeline
OneSCM
TAKE Business Cloud
Social enterprise- perception tracking, Customer insight &
service
Products in Pipeline
23
Spend Analytics Supplier Performance Supplier Selection Contract Administration Consulting & Insight NAFTA Compliance AP automation Catalog Services Supplier Enablement Invoice Processing Requisition Processing Reverse Engineering Value Engineering Prototyping Simulation & Testing Design Drawing & Documentation
24
Augmenting product & service offerings to enhance overall customer
experience and business transformation
Investing in new engagement models to drive the demand such as Software as
a Service (SaaS)
Increase penetration in high potential geographies (e.g. Europe, Emerging
Markets) in addition to consolidation of presence in existing markets (US, Middle East, Asia)
Forging alliances with leading ERP vendors to drive visibility, expand reach &
increase volumes
25
– Pent-up demand and revival of investment in ERP is driving software sales
– Outcome oriented end-to-end process outsourcing driving consulting and business services revenue
business services – Subscription and software as a service driving Supply Chain on the cloud
– Leverage success of US model in Europe – Build on the leadership position in the Middle East
26
Pharma & Medical Industrial Products/ Services Consumer Products High Tech FMCG / Food Oil & Gas
28
Strong growth and momentum across the operating segments
Revenue (Rs Mn) EBITDA (Rs Mn) EPS (Rs) PAT (Rs Mn)
2,939 3,354 3,518 5,003 7,037 FY08 FY09 FY10 FY11 FY12 765 704 521 1,033 1,451 FY08 FY09 FY10 FY11 FY12 529 528 324 700 856 FY08 FY09 FY10 FY11 FY12 4.74 4.44 2.70 5.83 7.13 FY08 FY09 FY10 FY11 FY12
29
Revenue By Category Revenue By Geography Revenue By Vertical
22% 23% 59% 65% 11% 10% 8% 2% FY11 FY12 Product License Business Services AMC Others
65% 63% 33% 31% 2% 6% FY11 FY12 US AsiaPac RoW 47% 51% 49% 44% 4% 5% FY11 FY12 LS SCM Others
30
Revenue By Category Revenue By Geography Revenue By Vertical
22% 21% 20% 65% 64% 67% 11% 11% 11% 2% 4% 2%
Q2FY12 Q1FY13 Q2FY13
Product License Business Services Amc Others 62% 61% 55% 31% 33% 38% 7% 6% 7%
Q2FY12 Q1FY13 Q2FY13
US Asia Pac RoW 50% 53% 48% 45% 43% 50% 5% 4% 2%
Q2FY12 Q1FY13 Q2FY13
LS SCM Others
31
1,173 1,249 1,496 1,586 1,674 1,849 1,927 2,178 2,117 8.2% 6.5% 19.8% 6.0% 5.6% 10.4% 4.3% 13.0%
0% 5% 10% 15% 20% 25% 500 1,000 1,500 2,000 Q2 FY11 Q3 FY11 Q4 FY11 Q1 FY12 Q2 FY12 Q3 FY12 Q4 FY12 Q1 FY13 Q2 FY13 INR million
Revenue
Net Revenue Growth q-o-q (%)
248 268 285 338 350 404 359 448 416 163 189 204 216 202 213 225 252 211 21.2% 21.5% 19.0% 21.3% 20.9% 21.8% 18.6% 20.6% 19.7% 0% 5% 10% 15% 20% 25% 100 200 300 400 500 Q2 FY11 Q3 FY11 Q4 FY11 Q1 FY12 Q2 FY12 Q3 FY12 Q4 FY12 Q1 FY13 Q2 FY13 INR million
Profitability
EBITDA Net Profit EBITDA Margin (%) Net Margin (%)
32
26.6 28.4 28.3 30.3 31.1 33.7 32.1 40.6 41.2 39.3 25.2 28.8 33.4 40.5 41.4 38.4 41.9 49.6 51.6 46.0
10 20 30 40 50 60 70 80 90 100
Q1FY11 Q2FY11 Q3FY11 Q4FY11 Q1FY12 Q2FY12 Q3FY12 Q4FY12 Q1FY13 Q2FY13
USD million
SCM LS 57.2 61.7 70.8 72.5 72.1 74.0 90.2 92.8 51.8 85.3
33
Category No of Shares % of Total Promoter & Promoter Group 73,772,314 60.3% Public Shareholding
Mutual Funds/Financial Institutions/ Banks 3,524,182 2.9% FIIs 2,628,722 2.1% Trust 2,765,422 2.3%
Bodies Corporate 15,446,937 12.6% Retail/Others 24,262,423 19.8% TOTAL 122,400,000 100.0%
Shareholding Patterns (Sept 30, 2012)
Promoter & Promoter Group 60.3% Mutual Funds/Financial Institutions/ Banks 2.9% FIIs 2.1% Trust 2.3% Bodies Corporate 12.6% Retail/Others 19.8%
35
to launch 6 products across LS and SCM over the next two years
customer focused solutions
with services
technologies & standards and incorporate them in
Right Product and Service Mix
into new geographies
revenue contribution from Europe to 20% over the next two years
momentum and leadership position in US and Asia Pacific
Exploring New Markets
Partnerships to make
products platform agnostic
Gate, Cegedim Dendrite, Firefox, Intermec, Liquent, Oracle & SAP
Right Investments
Growth Enablers
36
Strong fundamentals
Growth momentum
Improving financials
37
Acronyms Meanings
CTMS Clinical Trial Management System EDC Electronic Data Capture CDMS Clinical Data Management System eDMS Electronic Document Management System eSub Electronic Submissions CDR Clinical Data Repository LSH Life Sciences Hub PV Pharmacovigilance IND Investigational New Drug CTA Clinical Trial Authorization NDA New Drug Application PaaS Platform as a Service ETL Extract Transform and Load PO collaboration Purchase Order Collaboration AP automation Accounts Payables Automation
Disclaimer:
This presentation has been prepared by TAKE Solutions Ltd. (the “Company”) solely for your information and for your use and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization or firm) or published in whole or in part, for any purpose. By attending this presentation, you are agreeing to be bound by the foregoing restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials. Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT including factors which may affect our cost advantage, wage increases, our ability to attract and retain highly skilled professionals, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in Supply Chain Management (SCM) & Life Sciences (LS), disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our contracts, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. TAKE does not undertake to update any forward- looking statement that may be made from time to time by or on behalf of the company.
TAKE: Technology, Analytics & Knowledge for the Enterprise
For further information, please contact: Sachin Garg sachingarg@takesolutions.com